GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » PT Soho Global Health Tbk (ISX:SOHO) » Definitions » Research & Development

PT Soho Global Health Tbk (ISX:SOHO) Research & Development : Rp25,492 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is PT Soho Global Health Tbk Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. PT Soho Global Health Tbk's Research & Development for the three months ended in Dec. 2024 was Rp7,064 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was Rp25,492 Mil.

PT Soho Global Health Tbk Research & Development Historical Data

The historical data trend for PT Soho Global Health Tbk's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PT Soho Global Health Tbk Research & Development Chart

PT Soho Global Health Tbk Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial 18,124.00 23,262.00 22,396.00 22,606.00 25,492.00

PT Soho Global Health Tbk Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,108.00 6,023.00 5,826.00 6,579.00 7,064.00

PT Soho Global Health Tbk Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp25,492 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Soho Global Health Tbk  (ISX:SOHO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

PT Soho Global Health Tbk Research & Development Related Terms

Thank you for viewing the detailed overview of PT Soho Global Health Tbk's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

PT Soho Global Health Tbk Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » PT Soho Global Health Tbk (ISX:SOHO) » Definitions » Research & Development
Comparable Companies
ISX:EPMT ISX:KAEF ISX:IRRA ISX:SDPC ISX:ZBRA MCK COR CAH ASX:SIG SHSE:601607 HSIC HKSE:01099 SHSE:600332 MIL:AMP XSWX:GALE NZSE:EBO SHSE:600998 TSE:7459 SHSE:600511 PDCO
Traded in Other Exchanges
N/A
Address
Jalan Rawa Sumur II Kav BB No. 3, Kawasan Industri Pulogadung, Kel., Jatinegara, Kec. Cakung, Jakarta Timur, Jakarta, IDN, 13930
Website
https://www.sohoglobalhealth.com
PT Soho Global Health Tbk is a healthcare company operating in the areas of natural/herbal health care products and services. The company manufactures and distributes pharmaceutical products to herbal cures, proprietary medicines and health foods under various brand names such as Curcuma Plus; Curcuma Plus Milk; Imboost; Fitkom; Diapet; Laxing; Lelap; Asthma Soho; and Sohobion. Its segment includes Distribution; Professional product; Consumer health; Alliance and others. The company generates maximum revenue from the Distribution segment.